Bharat Biotech & SII jointly pledge to provide global access for COVID-19 vaccines

MUMBAI: Adar Poonawala (Chief Executive Officer Chairman of Serum Institute of India) and Krishna Ella (Chairman & Managing Director of Bharat Biotech), jointly communicated their combined intent to develop manufacture, and supply the COVID-19 vaccines for India and globally. This development came after a series of cross-statements made by the two companies in the past two days.

They said that the most important task in front of them is saving the lives and livelihoods of populations in India and the world.

"Vaccines are a global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest," they stated.

ALSO READ: Smriti Irani assures Assam MP Khaleque of Centre's help to preserve state's bell metal industry

"Now that two COVID-19 vaccines have been issued EUA (emergency use authorization) in India, the focus is on manufacturing, supply and distribution, such that populations that need it the most receive high quality, safe and efficacious vaccines. Both our Companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines," their joint statement by Bharat Biotech and the SII further read.

Serum Institute of India CEO Adar Poonawalla earlier today said exports of its vaccine, Covishield, which became one of the first Covid-19 vaccines in India to get restricted emergency-use approval, are permitted to all countries.

To support our brand of fearless and investigative journalism, support us HERE. 

Download:                                                                   

The Inside Northeast app HERE for News, Views, and Reviews from Northeast India. 

Do keep following us for news on-the-go. We deliver the Northeast